Beta-Blocker Interruption or Continuation after Myocardial Infarction: NEJM 🥸Abyss trial is a very interesting name! 😱30 points summary! 👇👇👇

Delighted to present these data today from the DETERMINE trials at the #ESCCongress The first evidence of a beneficial effect of a HF therapy on accelerometer-based measures of physical activity. A promising new outcome measure for HF trials.

ESC guidelines for PCI in severe LV impairment changed from 2a LoE C (should be done in most patients, based on consensus) to 2b LoE B (may be done in selected patients, based on randomised data).#ESCCongress 🙏🏽REVIVED investigators for providing the supporting evidence

RESHAPE-HF2 shows no impact on mortality but significant reduction in HFH and improvement in KCCQ. All call for a larger trial to confirm MTEER for lower risk and lower MR severity. #ESC2024

Beta-blocker use and outcomes in patients with #HeartFailure and mildly reduced and preserved ejection fraction released at #ESCCongress and just published in #EJHF👉 bit.ly/3Tbt2hr EJHF Editor-in-Chief Faiez ZANNAD

Ischemia analysis of REVIVED #ESCCongress 💜 approx 20% of LV scarred 30% ischemic on CMR 🏥 very high rates of death or aborted sudden death 📈 amount of ischemia not associated with risk of events 📈 no benefit of PCI whether ischemia extensive or mild/moderate

While the rest of Ireland and the UK are fighting for Oasis tickets, I’m at this Rockstar line-up of HF cardiologists listening to their wisdom, and proud to call many my friends and mentors ❤️ Emer Joyce Maria Rosa Costanzo #ESCCongress2024

🔥 Fresh presentation at #ESC 2024 European Society of Cardiology 🔥 🔥 Fresh publication in JACC Journals 🔥 Our work on this secondary analysis of: #TRILUMINATE Impact of Renal & Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair | Journal of the

FRESH OFF THE PRESS - New study in European Society of Cardiology European Society of Cardiology Journals Prediction of incident atrial fibrillation using deep learning, clinical models and polygenic scores shows #AI can predict new-onset atrial fibrillation from ECGs with high accuracy, outperforming clinical and genetic

Patricia Campbell speaking now at the joint meeting European Society of Cardiology #CouncilforCardiologyPractice and Primary Care Cardiovascular Society

#FINEARTS-HF : #Finerenone in #HFmrEF or #HFpEF 📍Double-blind trial of 6001 patients with #HeartFailure and LVEF ≥40% 📍⬇️ primary outcome events by 16% compared to placebo (rate ratio 0.84; 95% CI 0.74-0.95; P=0.007) over 32 months. 📍Worsening HF events were 18% lower

#ESCCongressVisuals for Hotline 7: FINEARTS-HF - #Finerenone in #HeartFailure with mildly reduced and preserved ejection fraction MRAs in #HF - An individual patient data meta-analysis of randomised trials FINE-HEART - Participant-level pooled analysis of finerenone in

Check out this critical #ESCCongress sim-pub! "Prevalence and Prognostic Implications of Changes in TR Severity during Acute HF" 💠Persistent TR groups had higher event rates 💠Significant TR after decongestion might be a target for further treatment 🔗 bit.ly/3z1I2Ys

Honored to be asked to chair a session at #ESCCongress on 'Rare causes of Heart Failure' Great cases and congratulations to the presenters. #functionnotfailure. #HFAYoungAmbassadorforIreland #irishintheUk IrishCardiacSociety

And finally my calendar is free so I can go learn! But what a fun session to finish in - collaboration with Primary Care Cardiovascular Society and European Society of Cardiology council for cardio care talking all things CKD and HFpEF. Integration of care between 1&2 level care is critical for excellence in care

Loving that we are realizing the BMI paradox way less important than visceral fat deposition for risk for HFpEF. A super session here with Amina and my HFpEF co-author Matthew Lee #ESCCongress2024

🚨FINEARTS-HF trial, finerenone reduced HF events and cardiovascular death in patients with HFmrEF/HFpEF🚨 #ESCCongress #FINEARTS #HFpEF #LBCT #ESCHotline 📎 nejm.org/doi/abs/10.105… 📍46%💃🏻 📍16% Asian 📍mean age 72y 📍not on top of SGLT2i 📍v symptomatic population

What does it take to have record breaking attendance at the global stage at #ESCCongress2024 ?? Just the IrishCardiacSociety and British Cardiovascular Society joint session 💥💥💥

#ESCCongress2024 **MATTERHORN Trial** RCT of mitral transcatheter edge-edge repair (mTEER) versus MV surgery in patients with HFrEF and at least moderate secondary MR A thread...

Excellent work Debar Rasoul - Full Paper onlinelibrary.wiley.com/doi/10.1002/eh…